Medimetriks Pharmaceuticals Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 1

  • Investments
  • 2

Medimetriks Pharmaceuticals General Information

Description

Operator of a specialty pharmaceutical company dedicated to the Dermatology and Podiatry markets. The company offers advanced patient care through the development, licensing and commercialization of innovative prescription skincare that treat conditions including acne, rosacea, atopic dermatitis, fungal infections, dystrophic nails and impetigo.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 383 Route 46 West
  • Fairfield, NJ 07004-2402
  • United States
+1 (973)
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Personal Products
Parent Company
Corporate Office
  • 383 Route 46 West
  • Fairfield, NJ 07004-2402
  • United States
+1 (973)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Medimetriks Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Medimetriks Pharmaceuticals‘s full profile, request access.

Request a free trial

Medimetriks Pharmaceuticals Investments (2)

Medimetriks Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with Medimetriks (U.S. Development And Commercialization Rights to OPA-15406) for . The deal was made on 08-Feb-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Medimetriks (U.S. Development And Commercialization Rights to OPA-15406) 08-Feb-2016 Corporate Asset Purchase Buildings and Property
Xepi (US Commercialization Rights) 01-Mar-2014 Corporate Asset Purchase Buildings and Property
To view Medimetriks Pharmaceuticals’s complete investments history, request access »

Medimetriks Pharmaceuticals Exits (1)

Medimetriks Pharmaceuticals’s most recent exit was on 01-Mar-2014 from Xepi (US Commercialization Rights). The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Xepi (US Commercialization Rights) 01-Mar-2014 Completed
To view Medimetriks Pharmaceuticals’s complete exits history, request access »

Medimetriks Pharmaceuticals FAQs

  • When was Medimetriks Pharmaceuticals founded?

    Medimetriks Pharmaceuticals was founded in 2008.

  • Where is Medimetriks Pharmaceuticals headquartered?

    Medimetriks Pharmaceuticals is headquartered in Fairfield, NJ.

  • What industry is Medimetriks Pharmaceuticals in?

    Medimetriks Pharmaceuticals’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Medimetriks Pharmaceuticals a private or public company?

    Medimetriks Pharmaceuticals is a Private company.

  • What is Medimetriks Pharmaceuticals’s current revenue?

    The current revenue for Medimetriks Pharmaceuticals is .

  • When was Medimetriks Pharmaceuticals acquired?

    Medimetriks Pharmaceuticals was acquired on 28-Nov-2022.

  • Who acquired Medimetriks Pharmaceuticals?

    Medimetriks Pharmaceuticals was acquired by Eurofarma Laboratorios.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process